These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 15374914)
1. Prescribing of lipid regulating drugs and admissions for myocardial infarction in England. Majeed A; Aylin P; Williams S; Bottle A; Jarman B BMJ; 2004 Sep; 329(7467):645. PubMed ID: 15374914 [No Abstract] [Full Text] [Related]
2. MI admissions fall following smoking ban in England. Savill P Practitioner; 2010; 254(1731):5. PubMed ID: 20812608 [No Abstract] [Full Text] [Related]
3. How do prescribing doctors anticipate the effect of statins? Lytsy P; Burell G; Westerling R J Eval Clin Pract; 2011 Jun; 17(3):420-8. PubMed ID: 20545813 [TBL] [Abstract][Full Text] [Related]
4. Drug treatment of hypertension. Conclusion of editorial is somewhat flawed. Hackam DG BMJ; 2003 Apr; 326(7392):764. PubMed ID: 12676853 [No Abstract] [Full Text] [Related]
5. Increasing prescription of drugs for secondary prevention of myocardial infarction. Lipid lowering drugs should be considered too. Taylor A; Reckless JP BMJ; 1996 Jan; 312(7025):252. PubMed ID: 8563613 [No Abstract] [Full Text] [Related]
6. [Prevention of myocardial infarction by chemotherapy]. Toshima H; Adachi K Nihon Rinsho; 1982; 40(11):2465-70. PubMed ID: 6130172 [No Abstract] [Full Text] [Related]
7. The other side of the bezafibrate infarction prevention trial data. McCormack J; Loewen P Arch Intern Med; 2005 Nov; 165(20):2431-2; author reply 2432. PubMed ID: 16287780 [No Abstract] [Full Text] [Related]
8. Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Burgess DC; Hunt D; Li L; Zannino D; Williamson E; Davis TM; Laakso M; Kesäniemi YA; Zhang J; Sy RW; Lehto S; Mann S; Keech AC Eur Heart J; 2010 Jan; 31(1):92-9. PubMed ID: 19797259 [TBL] [Abstract][Full Text] [Related]
9. Lipid-lowering therapy after myocardial infarction: the Bavarian Cholesterol Screening Project. Richter WO; Schwandt P JAMA; 1998 Aug; 280(7):603-4. PubMed ID: 9718050 [No Abstract] [Full Text] [Related]
10. Effect of the metabolic syndrome and hyperuricemia on outcome in patients with coronary artery disease (from the Bezafibrate Infarction Prevention Study). Brodov Y; Behar S; Boyko V; Chouraqui P Am J Cardiol; 2010 Dec; 106(12):1717-20. PubMed ID: 21126615 [TBL] [Abstract][Full Text] [Related]
12. Testing the efficacy of lipid-lowering therapy versus revascularization: the time has come, or is it past due? Enas EA Circulation; 1998 Jun; 97(25):2584-6. PubMed ID: 9657483 [No Abstract] [Full Text] [Related]
13. Lipoprotein(a) measurement and determining risk of myocardial infarction. Jones SR; Blumenthal RS JAMA; 2009 Oct; 302(15):1645; author reply 1645-6. PubMed ID: 19843896 [No Abstract] [Full Text] [Related]
14. Combined secondary prevention after hospitalization for myocardial infarction in France: analysis from a large administrative database. Tuppin P; Neumann A; Danchin N; Weill A; Ricordeau P; de Peretti C; Allemand H Arch Cardiovasc Dis; 2009 Apr; 102(4):279-92. PubMed ID: 19427605 [TBL] [Abstract][Full Text] [Related]
15. The cholesterol controversy. Rybinski EA BMJ; 1992 Mar; 304(6828):712. PubMed ID: 1571654 [No Abstract] [Full Text] [Related]
17. The ALLHAT trial: a verdict or a challenge? Zanchetti A; Mancia G J Hypertens; 2003 Feb; 21(2):223. PubMed ID: 12569240 [No Abstract] [Full Text] [Related]
18. Demand for hospital services following admission with suspected myocardial infarction in 1983 and 1989. Hampton P; Harrison L; Gray D Health Trends; 1993; 25(3):91-4. PubMed ID: 10131870 [TBL] [Abstract][Full Text] [Related]
19. Air pollution and hospital admissions for myocardial infarction in a subtropical city: Taipei, Taiwan. Hsieh YL; Yang YH; Wu TN; Yang CY J Toxicol Environ Health A; 2010; 73(11):757-65. PubMed ID: 20391118 [TBL] [Abstract][Full Text] [Related]
20. [Reduction in 28 days and 6 months of acute myocardial infarction mortality from 1995 to 2005. Data from PRIAMHO I, II and MASCARA registries]. Arós F; Heras M; Vila J; Sanz H; Ferreira-González I; Permanyer-Miralda G; Cuñat J; López-Bescós L; Cabadés A; Loma-Osorio A; Marrugat J; Rev Esp Cardiol; 2011 Nov; 64(11):972-80. PubMed ID: 21803474 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]